Silk Road Medical reports Q4 EPS (33c), consensus (42c)

Reports Q3 revenue $47.27M , consensus $41.97M . Reports adjusted EBITDA was a loss of $4.1M for the fourth quarter of 2023 compared to a loss of $4.4 M for the fourth quarter of 2022.”With the right team in place, broad reimbursement, and extensive evidence in support of TCAR, we are laser focused on deepening adoption in physicians who perform TCAR,” said Chas McKhann, CEO of Silk Road Medical. “My experience thus far at Silk Road has only served to further validate the vast opportunity that we see for TCAR to benefit many more patients with carotid artery disease, and I’m excited by the underlying progress we are already making towards that end.”